Cargando…

Strategies for enhancing CAR T cell expansion and persistence in HIV infection

Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothemejer, Frederik Holm, Lauritsen, Nanna Pi, Søgaard, Ole Schmeltz, Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475529/ https://www.ncbi.nlm.nih.gov/pubmed/37671164 http://dx.doi.org/10.3389/fimmu.2023.1253395

Ejemplares similares

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
por: Hvilsom, Caroline Thue, et al.
Publicado: (2021)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization
por: Klastrup, Vibeke, et al.
Publicado: (2022)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response
por: Søgaard, Ole Schmeltz
Publicado: (2022)

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
por: Kong, Yingjie, et al.
Publicado: (2023)

Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis
por: Ostrowski, Sisse R., et al.
Publicado: (2021)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Advances in Developing CAR T-Cell Therapy for HIV Cure
por: Qi, Jinxin, et al.
Publicado: (2020)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
por: Kremer, Jakob, et al.
Publicado: (2022)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
por: González-Brito, Adrián, et al.
Publicado: (2023)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
por: Jafarzadeh, Leila, et al.
Publicado: (2020)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Polysaccharide Responsiveness Is Not Biased by Prior Pneumococcal-Conjugate Vaccination
por: Bernth-Jensen, Jens Magnus, et al.
Publicado: (2013)

A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy
por: Ferry, Gabrielle M., et al.
Publicado: (2022)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy
por: Li, Wenshuai, et al.
Publicado: (2023)

From barriers to novel strategies: smarter CAR T therapy hits hard to tumors
por: Khawar, Muhammad Babar, et al.
Publicado: (2023)

Editorial: HIV-Associated Immune Activation and Persistent Inflammation
por: Hoenigl, Martin, et al.
Publicado: (2019)

DC-based immunotherapy as strategy to purge the HIV reservoir?
por: Søgaard, Ole S.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2o5g8fq6h533qtlrqte6rnqksf